Intervacc AB (fra:2E9) Share Price

Company Profile

Business description
Intervacc AB is a Swedish animal health company that develops, manufactures and commercializes veterinary vaccines based on its proprietary recombinant fusion protein technology platform. Its product, Strangvac, is a vaccine against equine strangles and is marketed across multiple European countries. The company is also developing Piggivac for Streptococcus suis infections in pigs and operates through animal health, veterinary pharmaceuticals and diagnostic services. Geographically, the company generates its revenue from Europe through vaccine sales and distribution partnerships, while expansion targets North America, Australia and New Zealand.
Contact
Vastertorpsvagen 135 B
Hagersten
StockholmS-129 44
SWE
T: +46 812010600
https://www.intervacc.se
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16

Recommended

These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.

Morningstar | 11 November 2026

There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.

Malik Ahmed Khan, CFA | 11 November 2026

Strong fundamentals meet a demanding valuation.

Esther Holloway | 11 November 2026

Index	Last price	Change	% Change
All Ordinaries	9,245.00	46.30	-0.50%
CAC 40	8,332.87	54.28	0.66%
DAX 40	26,662.77	315.32	1.20%
Dow JONES (US)	52,486.49	254.60	0.49%
FTSE 100	10,835.47	83.88	0.78%
HKSE	23,997.75	318.17	-1.31%
NASDAQ	25,466.19	400.32	1.60%
Nikkei 225	61,714.16	465.57	0.76%
NZX 50 Index	14,259.06	79.20	0.56%
S&P 500	7,619.38	98.45	1.31%
S&P/ASX 200	9,112.70	40.50	-0.44%
SSE Composite Index	3,689.17	8.52	0.23%